|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
RARβ, TMEFF2 and CYGB displayed no apparent methylation, while a combinatory epigenotype based on p16, hTERT, RASSF1 and WT1 was associated with a significantly higher chance of detecting malignancy in any positive sample (odds ratio: 24, 95% CI: 4.7-125, P<0.001).
|
21063414 |
2010 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, the putative mechanisms of Cygb expression in cancer were explored by subjecting HNSCC cell lines to hypoxic culture conditions and 5-aza-2-deoxycitidine treatment.
|
19568272 |
2009 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We conclude that the CYGB gene is regulated by both promoter methylation and tumour hypoxia in HNSCC and that increased expression of this gene correlates with clincopathological measures of a tumour's biological aggression.
|
19568272 |
2009 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, the putative mechanisms of Cygb expression in cancer were explored by subjecting HNSCC cell lines to hypoxic culture conditions and 5-aza-2-deoxycitidine treatment.
|
19568272 |
2009 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CYGB is assigned to chromosomal region 17q25, which is frequently lost in multiple malignancies.
|
18794132 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoglobin: a novel potential gene medicine for fibrosis and cancer therapy.
|
18691024 |
2008 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We showed that the tumor specificity of CYGB methylation in discriminating patients with and without lung cancer, using biopsies and sputum samples.
|
18794132 |
2008 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoglobin: a novel potential gene medicine for fibrosis and cancer therapy.
|
18691024 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoglobin is a novel candidate tumour suppressor gene highly methylated in upper aero-digestive tract squamous cancer.
|
16449996 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYGB expression in tumour tissue was significantly reduced compared with corresponding adjacent normal in 54% of the examined cases (paired t-test, P<0.001).
|
16698880 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant CpG methylation of gene promoters within tumour specimens was found in 28% for p16, 73% for RARbeta, 42% for E-cadherin, 65% for cytoglobin and 53% for cyclinA1.
|
16449996 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoglobin is a novel candidate tumour suppressor gene highly methylated in upper aero-digestive tract squamous cancer.
|
16449996 |
2006 |
|
Retinitis Pigmentosa
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
RETINITIS PIGMENTOSA 36
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Ectopic CYGB expression suppressed proliferation, migration, invasion and induced apoptosis in breast cancer cell lines MCF7 (p53WT) and MB231 (p53mt) in vitro, and inhibited xenograft tumor growth in vivo.
|
30545372 |
2018 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Ectopic CYGB expression suppressed proliferation, migration, invasion and induced apoptosis in breast cancer cell lines MCF7 (p53WT) and MB231 (p53mt) in vitro, and inhibited xenograft tumor growth in vivo.
|
30545372 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The ΔNp63-CYGB axis is also present in lung and breast cancer cell lines, indicating that CYGB-mediated ROS-scavenging activity may also have a role in epithelial tumours.
|
26096935 |
2016 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The ΔNp63-CYGB axis is also present in lung and breast cancer cell lines, indicating that CYGB-mediated ROS-scavenging activity may also have a role in epithelial tumours.
|
26096935 |
2016 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
This is the first time that HB and CYGB are reported in breast cancer.
|
20958924 |
2011 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Breast carcinomas showed the tendency to silence CYGB.
|
20958924 |
2011 |
|
Malignant neoplasm of breast
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
By nested methylation-specific DNA sequencing analysis of lung and breast cancer cell lines and bronchial and mammary epithelial cell lines, we identified that methylation of a 110-bp CpG-rich segment of the CYGB promoter was correlated with gene silencing.
|
18794132 |
2008 |
|
Breast Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
By nested methylation-specific DNA sequencing analysis of lung and breast cancer cell lines and bronchial and mammary epithelial cell lines, we identified that methylation of a 110-bp CpG-rich segment of the CYGB promoter was correlated with gene silencing.
|
18794132 |
2008 |
|
Anemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
3-MCPD significantly reduced RBC, HGB and HCT levels, indicating a phenotype of anemia, which returned to normal after the recovery period.
|
30453003 |
2019 |
|
Anemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
In derivation cohort, anemia (HGB < 90g/L), tuberculous meningitis, severe pneumonia, hypoalbuminemia, unexplained infections or space-occupying lesions, and malignancies remained independent risk factors of mortality in HIV/TB co-infected patients, and included in this clinical scoring model.
|
30930360 |
2019 |
|
Anemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The patients were randomly assigned into derivation cohort (801cases) and validation cohort (200 cases) in 8:2 ratio, respectively, in which in derivation cohort we found that 7 predictors, including LDH >350U/L, HR>130 times/min, room air PaO<sub>2</sub> <70mmHg, later admission to ICU, Anemia (HGB≤90g/L), CD4<50cells/ul, and development of a pneumothorax, were associated with poor prognosis in HIV/AIDS patients with PCP and were included in the predictive model.
|
30906778 |
2019 |